Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v24-FR | Version v11-FR | |
---|---|---|
Language | French | French |
Date Updated | 2023-01-19 | 2022-11-29 |
Drug Identification Number | 00399736 | 00399736 |
Brand name | L-ARGININE HYDROCHLORIDE INJECTION | L-ARGININE HYDROCHLORIDE INJECTION |
Common or Proper name | L-ARGININE HCL | L-ARGININE HCL |
Company Name | SANDOZ CANADA INCORPORATED | SANDOZ CANADA INCORPORATED |
Ingredients | ARGININE HYDROCHLORIDE | ARGININE HYDROCHLORIDE |
Strength(s) | 250MG | 250MG |
Dosage form(s) | LIQUID | LIQUID |
Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVENOUS INTRAVENOUS |
Packaging size | 30ML 1LIVI | 30ML 1LIVI |
ATC code | V04CD | V04CD |
ATC description | OTHER DIAGNOSTIC AGENTS | OTHER DIAGNOSTIC AGENTS |
Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
Anticipated start date | ||
Actual start date | 2022-09-02 | 2022-09-02 |
Estimated end date | 2022-12-27 | 2022-12-16 |
Actual end date | 2023-01-18 | |
Shortage status | Resolved | Actual shortage |
Tier 3 Status | No | No |
Company comments | Baxter item : 1060 Product is available on allocation based on 90% of historical volumes | Baxter item : 1060 50% allocation |
Health Canada comments |